Research programme: complement factor D inhibitors - Achillion PharmaceuticalsAlternative Names: ACH CFDIS
Latest Information Update: 23 Mar 2017
At a glance
- Originator Achillion Pharmaceuticals
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Complement factor D inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration; Chronic obstructive pulmonary disease